Samit Ganguly
Regeneron (United States)(US)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Tuberculosis Research and Epidemiology, Drug Transport and Resistance Mechanisms, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → In Vitro and In Vivo Efficacy of β-Lactams against Replicating and Slowly Growing/Nonreplicating Mycobacterium tuberculosis(2013)80 cited
- → Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development(2023)79 cited
- → Thiazolopyridine Ureas as Novel Antitubercular Agents Acting through Inhibition of DNA Gyrase B(2013)66 cited
- → Novel N-Linked Aminopiperidine-Based Gyrase Inhibitors with Improved hERG and in Vivo Efficacy against Mycobacterium tuberculosis(2014)51 cited
- → Thiazolopyridone ureas as DNA gyrase B inhibitors: Optimization of antitubercular activity and efficacy(2013)41 cited
- → Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling(2021)37 cited
- → Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants(2021)33 cited
- → Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice(2018)33 cited
- → Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19(2022)32 cited
- → Effect of Coadministration of Moxifloxacin and Rifampin on Mycobacterium tuberculosis in a Murine Aerosol Infection Model(2012)24 cited